165 related articles for article (PubMed ID: 21906599)
1. Statistical considerations for calculation of immunogenicity screening assay cut points.
Hoffman D; Berger M
J Immunol Methods; 2011 Oct; 373(1-2):200-8. PubMed ID: 21906599
[TBL] [Abstract][Full Text] [Related]
2. A novel gamma-fitting statistical method for anti-drug antibody assays to establish assay cut points for data with non-normal distribution.
Schlain B; Amaravadi L; Donley J; Wickramasekera A; Bennett D; Subramanyam M
J Immunol Methods; 2010 Jan; 352(1-2):161-8. PubMed ID: 19891969
[TBL] [Abstract][Full Text] [Related]
3. Statistical evaluation of several methods for cut-point determination of immunogenicity screening assay.
Shen M; Dong X; Tsong Y
J Biopharm Stat; 2015; 25(2):269-79. PubMed ID: 25356783
[TBL] [Abstract][Full Text] [Related]
4. Correlation of screening and confirmatory results in tiered immunogenicity testing by solution-phase bridging assays.
Kubiak RJ; Zhang L; Zhang J; Zhu Y; Lee N; Weichold FF; Yang H; Abraham V; Akufongwe PF; Hewitt L; Robinson S; Liu W; Liu X; Patnaik MM; Spitz S; Wu Y; Roskos LK
J Pharm Biomed Anal; 2013 Feb; 74():235-45. PubMed ID: 23245256
[TBL] [Abstract][Full Text] [Related]
5. Application of analytical detection concepts to immunogenicity testing.
Klakamp SL; Lu H; Tabrizi M; Funelas C; Roskos LK; Coleman D
Anal Chem; 2007 Nov; 79(21):8176-84. PubMed ID: 17922557
[TBL] [Abstract][Full Text] [Related]
6. Non-normal random effects models for immunogenicity assay cut point determination.
Zhang J; Yu B; Zhang L; Roskos L; Richman L; Yang H
J Biopharm Stat; 2015; 25(2):295-306. PubMed ID: 25356500
[TBL] [Abstract][Full Text] [Related]
7. Elucidation of the statistical factors that influence anti-drug antibody cut point setting through a multi-laboratory study.
Nishimura K; Shibata H; Aoyama M; Hosogi J; Kadotsuji K; Minoura K; Mori T; Nakamura T; Nishimiya K; Nomura T; Saito T; Soma M; Wakabayashi H; Sakamoto N; Niimi S; Katori N; Saito Y; Ishii-Watabe A
Bioanalysis; 2019 Mar; 11(6):509-524. PubMed ID: 30945932
[No Abstract] [Full Text] [Related]
8. Statistical methods and tool for cut point analysis in immunogenicity assays.
Zhang L; Zhang JJ; Kubiak RJ; Yang H
J Immunol Methods; 2013 Mar; 389(1-2):79-87. PubMed ID: 23305975
[TBL] [Abstract][Full Text] [Related]
9. An immunoinhibition approach to overcome the impact of pre-existing antibodies on cut point establishment for immunogenicity assessment of moxetumomab pasudotox.
Schneider AK; Vainshtein I; Roskos LK; Chavez C; Sun B; Liang M
J Immunol Methods; 2016 Aug; 435():68-76. PubMed ID: 27220271
[TBL] [Abstract][Full Text] [Related]
10. A new method for identification of outliers in immunogenicity assay cut point data.
Zhang J; Arends RH; Kubiak RJ; Roskos LK; Liang M; Lee N; Chen CC; Yang H
J Immunol Methods; 2020; 484-485():112817. PubMed ID: 32615125
[TBL] [Abstract][Full Text] [Related]
11. Sample size consideration for immunoassay screening cut-point determination.
Zhang J; Zhang L; Yang H
J Biopharm Stat; 2014; 24(3):535-45. PubMed ID: 24697778
[TBL] [Abstract][Full Text] [Related]
12. A formal comparison of different methods for establishing cut points to distinguish positive and negative samples in immunoassays.
Jaki T; Lawo JP; Wolfsegger MJ; Singer J; Allacher P; Horling F
J Pharm Biomed Anal; 2011 Jul; 55(5):1148-56. PubMed ID: 21561734
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of therapeutics: a matter of efficacy and safety.
Nechansky A; Kircheis R
Expert Opin Drug Discov; 2010 Nov; 5(11):1067-79. PubMed ID: 22827745
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity assay cut point determination using nonparametric tolerance limit.
Zhang J; Li W; Roskos LK; Yang H
J Immunol Methods; 2017 Mar; 442():29-34. PubMed ID: 28063769
[TBL] [Abstract][Full Text] [Related]
15. Criteria to Reevaluate Anti-drug Antibody Assay Cut Point Suitability in the Target Population.
Tan CY; Steeno GS; You Z; Gaitonde P; Cai CH; Kamerud J; Gorovits B; Baltrukonis DJ
AAPS J; 2020 Jan; 22(2):19. PubMed ID: 31900604
[TBL] [Abstract][Full Text] [Related]
16. [The prediction of immunogenicity of therapeutic proteins].
Maillère B; Delluc S; Ravot G
Med Sci (Paris); 2012 Jan; 28(1):82-8. PubMed ID: 22289835
[TBL] [Abstract][Full Text] [Related]
17. Clinical immunogenicity specificity assessments: a platform evaluation.
Peng K; Siradze K; Quarmby V; Fischer SK
J Pharm Biomed Anal; 2011 Feb; 54(3):629-35. PubMed ID: 21035975
[TBL] [Abstract][Full Text] [Related]
18. Comparison of competitive ligand-binding assay and bioassay formats for the measurement of neutralizing antibodies to protein therapeutics.
Finco D; Baltrukonis D; Clements-Egan A; Delaria K; Gunn GR; Lowe J; Maia M; Wong T
J Pharm Biomed Anal; 2011 Jan; 54(2):351-8. PubMed ID: 20863644
[TBL] [Abstract][Full Text] [Related]
19. A false sense of security? Can tiered approach be trusted to accurately classify immunogenicity samples?
Jaki T; Allacher P; Horling F
J Pharm Biomed Anal; 2016 Sep; 128():166-173. PubMed ID: 27262992
[TBL] [Abstract][Full Text] [Related]
20. Challenges in developing antidrug antibody screening assays.
Dodge R; Daus C; Yaskanin D
Bioanalysis; 2009 Jul; 1(4):699-704. PubMed ID: 21083131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
